Table 3 Primary Variant Diagnosis and Related Treatment, by Case Variant

(a). Primary Variant Diagnosis

Nonadherence (Variant NA)

R1

R2

p-value

Control

2.6%

2.7%

0.989

Intervention 1

1.3%

39.0%

< 0.001

Intervention 2

4.8%

14.8%

0.031

p-value

0.414

< 0.001

DDI (Variant DDI)

R1

R2

p-value

Control

9.2%

9.3%

0.979

Intervention 1

6.5%

57.1%

< 0.001

Intervention 2

9.6%

18.5%

0.102

p-value

0.745

< 0.001

Other (apixaban resistance, HF progression, HTN-caused symptoms) (Variant AND)

R1

R2

p-value

Control

50.0%

72.0%

0.006

Intervention 1

64.9%

57.1%

0.321

Intervention 2

66.3%

58.0%

0.277

p-value

0.071

0.105

(b) CMD-related Primary Treatment

Continue stopped medication (Variant NA)

R1

R2

p-value

Control

6.6%

5.3%

0.747

Intervention 1

14.3%

35.1%

0.003

Intervention 2

9.6%

13.6%

0.430

p-value

0.283

< 0.001

Stop/switch interacting substance (Variant DDI)

R1

R2

p-value

Control

32.9%

12.0%

0.002

Intervention 1

32.5%

64.9%

< 0.001

Intervention 2

39.8%

21.0%

0.009

p-value

0.553

< 0.001

Other (shift med, advise HF progression, HTN workup) (Variant AND)

R1

R2

p-value

Control

14.5%

32.0%

0.011

Intervention 1

23.4%

28.6%

0.462

Intervention 2

25.3%

33.3%

0.258

p-value

0.211

0.803